Vilazodone Hydrochloride interactions
Checked as Vilazodone in this data source.
Full monograph for Vilazodone HydrochlorideCheck it against another medicine
Medicines
278 documented
Mechanism
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Almotriptan | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Amitriptyline Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Bupropion Hydrochloride | Major | Synergy | The use of bupropion is associated with a dose-related risk of seizures. The risk may be further increased when coadministered with selective serotonin… | 19 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme. | 4 sources — open the full entry |
| Citalopram Hydrobromide | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Clarithromycin | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme. | 4 sources — open the full entry |
| Clomipramine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Cyclobenzaprine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Desvenlafaxine Succinate | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Dextromethorphan + Bupropion | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…2 documented mechanisms | 119 sources — open the full entry |
| Dextromethorphan + Phenylephrine + Triprolidine | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Dextromethorphan + Pseudoephedrine + Triprolidine | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Dextromethorphan Hydrobromide | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Dextromethorphan Hydrobromide + Guaifenesin | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Dextromethorphan Polistirex | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Diphenhydramine + Dextromethorphan + Levomenthol | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Doxepin (Oral) | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Doxepin (Topical) | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Duloxetine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Escitalopram Oxalate | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme. | 4 sources — open the full entry |
| Fentanyl Citrate | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Fluoxetine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Fluphenazine + Nortriptyline | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1…2 documented mechanisms | 102 sources — open the full entry |
| Fluvoxamine Maleate | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Granisetron | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Guaifenesin + Dextromethorphan + Menthol | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Imipramine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Iohexol | Major | Synergy | Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of… | 5 sources — open the full entry |
| Iopamidol | Major | Synergy | Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of… | 5 sources — open the full entry |
| Itraconazole | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme. | 4 sources — open the full entry |
| Ketoconazole | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme. | 4 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme. | 4 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme. | 4 sources — open the full entry |
| Lasmiditan Hemisuccinate | Major | Synergy | Coadministration of lasmiditan and serotonergic agents may increase the risk of serotonin syndrome. Lasmiditan binds to the 5-HT(1F) receptor, where it… | 5 sources — open the full entry |
| Levomilnacipran Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Linezolid | Major | Synergy | Coadministration of linezolid with serotonergic agents may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal… | 52 sources — open the full entry |
| Lithium Carbonate | Major | Synergy | Lithium may enhance the pharmacologic effects of serotonin reuptake inhibitors (e.g., SSRIs, SNRIs, nefazodone, trazodone) and potentiate the risk of serotonin… | 22 sources — open the full entry |
| Lopinavir + Ritonavir | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme. | 4 sources — open the full entry |
| Maprotiline Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Milnacipran Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 102 sources — open the full entry |
| Mirtazapine | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Nelfinavir | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme. | 4 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme. | 4 sources — open the full entry |
| Nortriptyline | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
| Ondansetron | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Palonosetron | Major | Synergy | Concomitant use of 5-HT3 receptor antagonists with agents that possess or enhance serotonergic activity such as selective serotonin reuptake inhibitors… | 7 sources — open the full entry |
| Paracetamol + Tramadol Hydrochloride | Major | Synergy | Due to its serotonergic activity, coadministration of tramadol with serotonin-enhancing drugs such as SSRIs, SNRIs, nefazodone, trazodone, and mirtazapine may… | 33 sources — open the full entry |
| Paroxetine Hydrochloride | Major | Synergy | Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1… | 100 sources — open the full entry |
Food & lifestyle
alcohol
ModerateSynergy
Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
What to do: Patients receiving vilazodone should be advised to avoid consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how vilazodone affects them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities. Vilazodone should be taken with food. Administration without food may result in inadequate drug concentrations and diminished effectiveness.
1 source
- "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC (2011):
Conditions
Conditions in which Vilazodone Hydrochloride needs care, as documented in this source.
Depressive Disorder
MajorAntidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older. Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide. Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes. Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider. Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.
15 sources
- "Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc. (2022):
- "Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals) (2022):
- "Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc (2019):
- "Product Information. Zyban (buPROPion)." GlaxoSmithKline (2021):
- "Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline (2020):
- "Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline (2020):
- "Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals) (2022):
- "Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc (2020):
Show all 15 sourcesShow fewer sources
- "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc (2021):
- "Product Information. Vraylar (cariprazine)." Allergan Inc (2019):
- "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc (2019):
- "Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals (2022):
- "Product Information. Viibryd (vilazodone)." Allergan, Inc. USA (2021):
- "Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America (2021):
- "Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc. (2022):
Bipolar Disorder
ModerateTherapy with vilazodone may cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.
1 source
- "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC (2011):
Epilepsy
ModerateTherapy with vilazodone should be administered cautiously in patients with epilepsy or a history of seizure disorder.
1 source
- "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC (2011):
Glaucoma, Angle-Closure
ModerateSome antidepressants exert mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy. Prior to initiating therapy with these agents, patients should be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible. The use of these drugs in patients with untreated anatomically narrow angles should be avoided.
3 sources
- "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb (2001):
- "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC (2011):
- "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America (2013):
Hemorrhage
ModerateSome antidepressants should be administered with caution in patients with an increased risk for hemorrhage. Patients should be advised to immediately report any signs and symptoms suggestive of bleeding complications, including ecchymosis, hematoma, epistaxis, and petechia.
2 sources
- "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC (2011):
- "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America (2013):
Hyponatremia
ModerateTreatment with vilazodone may cause hyponatremia, in many cases secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.
1 source
- "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC (2011):
Therapeutic duplication
Drug classes that overlap with Vilazodone Hydrochloride, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Bupropion/dextromethorphan
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Fluoxetine/olanzapine
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Limbitrol ds
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Bupropion/naltrexone
antidepressants
The recommended maximum number of medicines in the 'antidepressants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antidepressants' category.
Example product in the source data (US market): Amitriptyline/perphenazine